	US 12,186,330 B2
	Compositions for improving cell viability and methods of use thereof
Joshua Cohen, Canton, MA (US); and Justin Klee, Cambridge, MA (US)
Assigned to Amylyx Pharmaceuticals Inc., Cambridge, MA (US)
Filed by Amylyx Pharmaceuticals Inc., Cambridge, MA (US)
Filed on Nov. 2, 2021, as Appl. No. 17/516,845.
Application 17/516,845 is a continuation of application No. 16/838,975, filed on Apr. 2, 2020, abandoned.
Application 16/838,975 is a continuation of application No. 16/781,239, filed on Feb. 4, 2020, granted, now 10,857,162, issued on Dec. 8, 2020.
Application 16/781,239 is a continuation of application No. 16/280,861, filed on Feb. 20, 2019, granted, now 11,071,742, issued on Jul. 27, 2021.
Application 16/280,861 is a continuation of application No. 15/837,866, filed on Dec. 11, 2017, granted, now 10,251,896, issued on Apr. 9, 2019.
Application 15/837,866 is a continuation of application No. 14/140,083, filed on Dec. 24, 2013, granted, now 9,872,865, issued on Jan. 23, 2018.
Claims priority of provisional application 61/804,690, filed on Mar. 24, 2013.
Prior Publication US 2022/0160733 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/575 (2006.01); A61K 31/192 (2006.01)

CPC A61K 31/575 (2013.01) [A61K 31/192 (2013.01)]

26 Claims

1. A method of treating at least one symptom of a tauopathy in a subject, the method comprising administering to the subject about 10 mg/kg to about 30 mg/kg of body weight of tauroursodeoxycholic acid (TUDCA) and about 30 mg/kg to about 100 mg/kg of body weight of sodium phenylbutyrate.